Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease

John Carroll

Editor & Founder

Albireo $ALBO CEO Ron Cooper is getting his long-awaited shot at marketing the first drug approved for pruritus in all subtypes of progressive familial intrahepatic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

How AI can address ongoing challenges in the life sciences industry

Al­bireo caps a big week with back-to-back ap­provals in the US/EU for the first drug to treat a se­vere liv­er dis­ease

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease